Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Norgine-Fennec

More Like This

PR Newswire associated0

Norgine announces Swissmedic approval of PEDMARQSI® for the prevention of cisplatin induced hearing loss in children

PR Newswire associated0

Norgine strengthens rare disease portfolio with acquisition of Theravia

PR Newswire associated0

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

PR Newswire associated0

Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology

PR Newswire associated0

Norgine B.V. submits Marketing Authorisation Application via Project Orbis for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

Ferring Pharmaceuticals bolsters global gene therapy supply chain with European manufacturing facility

PR Newswire associated0

Norgine announces £23 million new investment as part of more than £50 million committed to expanding medicines manufacturing in Wales

PR Newswire associated0

Norgine completes acquisition of Theravia